Aricept (Donepezil HCl) Patent Expiration, LOE Window & CMS Spending

Aricept (Donepezil HCl) by Eisai: FDA Orange Book LOE 2026-10-04, 20 AB generics, $1.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEisai
FDA Application & PathwayN020690 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-10-04
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors20
2024 CMS Total Public Spend$1.2M
2024 Medicare Part D Spend$1.2M
2024 Medicaid Spend$59K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.